Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

4D pharma press release feed
Presentations
4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)
26 Nov 2020, 07:10
Merger completion and NASDAQ listing expected in Q1 2021. US listing will support and accelerate…
Clinical
4D pharma presents new data from two MRx0518 clinical trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
9 Nov 2020, 13:03
MRx0518 demonstrates upregulation of key immune biomarkers associated with anti-cancer activity in…
Presentations
4D to Host Virtual KOL Event Reviewing MRx0518 Data To Be Presented at SITC 2020
5 Nov 2020, 12:00
4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the SITC Annual Meeting 2020…
4D pharma plc announces merger with Longevity, a special purpose acquisition company (SPAC), and its intention to gain a NASDAQ listing
22 Oct 2020, 07:00
4D pharma plc announces merger with Longevity, a special purpose acquisition company (SPAC), and its…
4D pharma announces topline results from Blautix® Phase II trial in irritable bowel syndrome (IBS)
7 Oct 2020, 07:00
4D pharma announces topline results from Blautix® Phase II BHT-II-002 trial in IBS-C and IBS-D
Directorate Change
23 Sep 2020, 07:00
4D pharma makes strategic appointment of independent Non-Executive Director in response to new…
4D hosts R&D webinar discussing the world-leading MicroRx® LBP discovery platform
1 Sep 2020, 10:00
4D pharma's Research Director, Dr Imke Mulder, and members of her Research team provide an overview…
Clinical Update - comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
26 Aug 2020, 07:30
4D pharma announces complete 6-month clinical benefit data from Part A of its ongoing trial of Live…
Clinical Update - 4D pharma treats first cancer patients in Part B of Phase I/II trial of MRx0518 in combination with Keytruda®
6 Jul 2020, 07:00
4D commences treatment of the first patients in Part B of its Phase I/II clinical trial of MRx0518…
Clinical Update - Phase II COVID-19 study open for enrolment
2 Jul 2020, 07:00
Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 open for enrolment. Dosing of…
4D hosts virtual R&D event providing updates on clinical programmes in oncology and COVID-19
5 Jun 2020, 07:45
4D's Chairman, CEO and CSO provide updates on the company’s clinical programmes in oncology and…
Clinical Update - Successful completion of immuno-oncology study safety phase
11 May 2020, 07:30
4D pharma plc announces successful completion of Part A of a Phase I/II clinical trial of MRx0518 in…
Clinical Update - Phase II COVID-19 study
20 Apr 2020, 07:00
4D announces expedited UK regulatory acceptance to commence Phase II study in COVID-19
Clinical Update - Interim analysis of Blautix Phase II study data
17 Apr 2020, 08:00
4D pharma plc today announces the key findings of a planned interim analysis in its BHT-II-0002…

BACK TO TOP